Patients with follicular lymphoma stage II and III who do not have a therapeutic indication may be treated with a watchful waiting strategy. For those with therapeutic indications, chemotherapy, biotherapy (single or combination therapy), ASCT (hematopoietic stem cell transplantation) and other treatments are available. 1. Chemotherapy: The chemotherapy regimens for stage II and III follicular lymphoma include CHOP (cyclophosphamide + doxorubicin + vincristine + ketorolac tromethamine) regimen, CVP (cyclophosphamide + vincristine + ketorolac tromethamine) regimen, or fludarabine-based regimen. 2. Biologic therapy: CD20 monoclonal antibody (rituximab) is often used in combination with chemotherapy regimens or as monotherapy with otuzumab. Maintenance therapy with rituximab or otolizumab monotherapy may improve survival, especially in patients who have achieved remission after first-line treatment or after relapse with reinduction therapy. 3. ASCT (hematopoietic stem cell transplantation): Study results show that ASCT may prolong survival in patients with sensitive relapses. Therefore, for patients who are still sensitive to chemotherapy after multiple relapses, they can participate in relevant clinical studies if they are young or in good physical status with normal vital organ function. The general principle of treatment for patients with follicular lymphoma stage II and III is to individualize the treatment plan according to the patient’s age, physical status, comorbidities, and therapeutic goals. Patients should actively cooperate with the doctor’s treatment, do not self-medicate to avoid delays or adverse reactions.